A BUDGET IMPACT MODEL FOR EPLERENONE IN THE TREATMENT OF HEART FAILURE POST MYOCARDIAL INFARCTION

Author(s)

Tabberer M1, Duerden M21Pfizer Ltd, Tadworth, Surrey, United Kingdom; 2 Keele University, Keele, Staffordshire, United Kingdom

OBJECTIVES: The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) showed that the addition of eplerenone to optimal medical therapy reduced both morbidity and mortality in patients with acute myocardial infarction (AMI) complicated by left ventricular dysfunction and heart failure whilst reducing the number and duration of heart failure re-hospitalisations. A budget impact model was developed to estimate the effects of adding eplerenone to standard care in the UK National Health Service (NHS). METHODS: Within the model the efficacy of eplerenone is based on the EPHESUS study. This is applied to UK epidemiological data on the incidence of AMI, proportion of survivors developing heart failure and their prognosis. UK drug acquisition costs and NHS hospital inpatient costs and average length of stay for England are included. All costs are expressed in pounds sterling. The model estimates the incremental costs and benefits of adding eplerenone to standard care in heart failure resulting from AMI from the perspective of NHS healthcare decision makers over a three-year period. Input variables include population, incidence of AMI and annual rate of eplerenone uptake. RESULTS: If all eligible patients are treated in an NHS Primary Care Trust of population 250,000, the estimated cost per life year saved is 6,701 pounds in year three, for an additional expenditure of 256,959 pounds. This level of treatment results in a reduction of 101 bed days for re-hospitalisations due to heart failure, at a cost per bed day avoided of 1,207 pounds. CONCLUSIONS: With hospital inpatient care the biggest single health care cost in heart failure, reduction in hospitalisation is a key priority within the UK NHS. Models such as the one described here enable the economic consequences of using a new drug to be identified and clarify the role of drug treatment in delivering NHS priorities.

Conference/Value in Health Info

2005-11, ISPOR Europe 2005, Florence, Italy

Value in Health, Vol. 8, No.6 (November/December 2005)

Code

PCV74

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×